{"id":5928,"date":"2024-05-29T13:00:00","date_gmt":"2024-05-29T06:00:00","guid":{"rendered":"https:\/\/www.globenewswire.com\/news-release\/2024\/05\/29\/2889543\/0\/en\/Anaveon-announces-IND-approval-of-ANV600-001-EXPAND-Phase-I-II-clinical-study.html2889543"},"modified":"2024-05-29T13:00:00","modified_gmt":"2024-05-29T06:00:00","slug":"anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study","status":"publish","type":"post","link":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/","title":{"rendered":"Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\/II clinical study"},"content":{"rendered":"\n<p align=\"center\"><strong>ANV600 combines a non-blocking \u03b1<\/strong><strong>PD-1 antibody and an IL-2R\u03b2\/\u03b3 selective agonist targeting IL-2<em> to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential<\/em><\/strong><\/p>\n<p align=\"justify\">BASEL, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) &#8212; Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug (IND) application to conduct a Phase I\/II study evaluating the safety and clinical activity of ANV600 has been accepted by the FDA. The Company will initiate the first two dose escalation cohorts with ANV600 monotherapy and combination with MSD\u2019s (Merck &amp; Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) as part of a multi cohort study to evaluate the safety and efficacy of ANV600 in multiple cancer indications.<\/p>\n<p align=\"justify\">ANV600 uses a non-blocking anti-PD-1 antibody to target a powerful IL-2R\u03b2\/\u03b3 selective IL-2 agonist to tumor-specific T cells, resulting in their proliferation and increase of tumor-killing potential. ANV600 is designed to administer in combination with approved PD-1 checkpoint inhibitors, thus enabling optimal dosing of IL-2 agonism and PD-1 blockade to maximize therapeutic benefit.<\/p>\n<p align=\"justify\">\u201cApproval to start our first-in-human clinical study of ANV600 represents an important step towards validation of our approach,\u201d <strong>said Eduard Gasal, M.D., Chief Medical Officer of Anaveon. <\/strong>\u201cIn preclinical studies, ANV600 has demonstrated marked efficacy and a favorable safety profile. We are eager to bring this potential treatment option to patients.\u201d<\/p>\n<p align=\"justify\">In March 2024, Anaveon entered into a clinical trial collaboration and supply agreement with MSD, to evaluate Anaveon\u2019s wholly-owned drug candidate ANV600 in combination with KEYTRUDA in clinical trials. Under the terms of the agreement, MSD will supply KEYTRUDA. Anaveon retains all worldwide rights to ANV600.<\/p>\n<p align=\"justify\">KEYTRUDA<sup>\u00ae<\/sup> is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA.<\/p>\n<p><strong>Media contact:<\/strong><br \/>JW Communications <br \/>Julia Wilson <br \/>Email: julia.wilson@anaveon.com<br \/>Tel: +44 (0)7818 430877<\/p>\n<p><strong>About Anaveon:<\/strong><br \/>Anaveon is a biotechnology company located in Basel, Switzerland. Using our immunological knowledge and expertise in protein engineering, we develop medicines to deliver meaningful benefits to cancer patients. Our lead compounds, ANV419 and ANV600, are currently in clinical trials in solid tumors.<\/p>\n<p>Find out more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XeQYAPnSt6i5dX7XXW5kZ7x3quT4el3A3pkJHf8c9SpdB0k4mH7IA37dl44OFiWrr7-3h5lbm3vpaPchIoi-1A==\" rel=\"nofollow noopener\" target=\"_blank\" title><strong>&gt;<\/strong> <strong>anaveon.com<\/strong><\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjUzNWRlYjMtMTAxMS00ZjhkLWI1MjgtNDEwODk5ZmY0Nzc5LTEyNDQ0MjE=\/tiny\/Anaveon.png\" referrerpolicy=\"no-referrer-when-downgrade\">  <\/p>\n","protected":false},"excerpt":{"rendered":"<p> ANV600 combines a non-blocking \u03b1PD-1 antibody and an IL-2R\u03b2\/\u03b3 selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential BASEL, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) &#8212; Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug (IND) application to conduct a Phase I\/II study evaluating the safety and clinical activity of ANV600 has been accepted by the FDA. The Company will initiate the first two dose escalation cohorts with ANV600&#8230;<\/p>\n","protected":false},"author":1,"featured_media":5929,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[75,1406],"tags":[],"class_list":["post-5928","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-globenewswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\/II clinical study<\/title>\n<meta name=\"description\" content=\"ANV600 combines a non-blocking \u03b1PD-1 antibody and an IL-2R\u03b2\/\u03b3 selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential BASEL, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug (IND) application to conduct a Phase I\/II study evaluating the safety and clinical activity of ANV600 has been accepted by the FDA. The Company will initiate the first two dose escalation cohorts with ANV600...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ANV600%20combines%20a%20non-blocking%20\u03b1PD-1%20antibody%20and%20an%20IL-2R\u03b2\/\u03b3%20selective%20agonist%20targeting%20IL-2%20to%20tumor-specific%20T%20cells%20resulting%20in%20proliferation%20and%20increase%20of%20tumor-killing%20potential%20BASEL,%20Switzerland,%20May%2029,%202024%20(GLOBE%20NEWSWIRE)%20--%20Anaveon,%20a%20clinical%20stage,%20immuno-oncology%20company,%20today%20announced%20that%20its%20Investigational%20New%20Drug%20(IND)%20application%20to%20conduct%20a%20Phase%20I\/II%20study%20evaluating%20the%20safety%20and%20clinical%20activity%20of%20ANV600%20has%20been%20accepted%20by%20the%20FDA.%20The%20Company%20will%20initiate%20the%20first%20two%20dose%20escalation%20cohorts%20with%20ANV600...\" \/>\n<meta property=\"og:locale\" content=\"vi_VN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\/II clinical study\" \/>\n<meta property=\"og:description\" content=\"ANV600 combines a non-blocking \u03b1PD-1 antibody and an IL-2R\u03b2\/\u03b3 selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential BASEL, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug (IND) application to conduct a Phase I\/II study evaluating the safety and clinical activity of ANV600 has been accepted by the FDA. The Company will initiate the first two dose escalation cohorts with ANV600...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Crypto Insider\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/yourcryptoinsider\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-29T06:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml.globenewswire.com\/media\/MjUzNWRlYjMtMTAxMS00ZjhkLWI1MjgtNDEwODk5ZmY0Nzc5LTEyNDQ0MjE=\/tiny\/Anaveon.png\" \/>\n<meta name=\"author\" content=\"Crypto Insider\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u0110\u01b0\u1ee3c vi\u1ebft b\u1edfi\" \/>\n\t<meta name=\"twitter:data1\" content=\"Crypto Insider\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u01af\u1edbc t\u00ednh th\u1eddi gian \u0111\u1ecdc\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 ph\u00fat\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/\"},\"author\":{\"name\":\"Crypto Insider\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#\\\/schema\\\/person\\\/e81ca31713268a414ddbed321d3383d6\"},\"headline\":\"Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\\\/II clinical study\",\"datePublished\":\"2024-05-29T06:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/\"},\"wordCount\":364,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study.gif\",\"articleSection\":[\"Business\",\"GlobeNewswire\"],\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/\",\"name\":\"Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\\\/II clinical study - Crypto Insider\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study.gif\",\"datePublished\":\"2024-05-29T06:00:00+00:00\",\"description\":\"Crypto and Blockchain News\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/#breadcrumb\"},\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vi\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study.gif\",\"contentUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study.gif\",\"width\":1,\"height\":1},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/category\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Business\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/category\\\/business\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\\\/II clinical study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#website\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/\",\"name\":\"Crypto Insider\",\"description\":\"Crypto and Blockchain News\",\"publisher\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vi\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#organization\",\"name\":\"Crypto Insider\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vi\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Logo-crypto-insider.jpeg\",\"contentUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Logo-crypto-insider.jpeg\",\"width\":2048,\"height\":2048,\"caption\":\"Crypto Insider\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/yourcryptoinsider\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/vietnaminsider\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#\\\/schema\\\/person\\\/e81ca31713268a414ddbed321d3383d6\",\"name\":\"Crypto Insider\",\"description\":\"Tin t\u1ee9c v\u1ec1 Ti\u1ec1n \u0111i\u1ec7n t\u1eed v\u00e0 c\u00f4ng ngh\u1ec7 Blockchain\",\"sameAs\":[\"https:\\\/\\\/cryptoinsider.asia\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\/II clinical study","description":"ANV600 combines a non-blocking \u03b1PD-1 antibody and an IL-2R\u03b2\/\u03b3 selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential BASEL, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug (IND) application to conduct a Phase I\/II study evaluating the safety and clinical activity of ANV600 has been accepted by the FDA. The Company will initiate the first two dose escalation cohorts with ANV600...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"ANV600 combines a non-blocking \u03b1PD-1 antibody and an IL-2R\u03b2\/\u03b3 selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential BASEL, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug (IND) application to conduct a Phase I\/II study evaluating the safety and clinical activity of ANV600 has been accepted by the FDA. The Company will initiate the first two dose escalation cohorts with ANV600...","og_locale":"vi_VN","og_type":"article","og_title":"Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\/II clinical study","og_description":"ANV600 combines a non-blocking \u03b1PD-1 antibody and an IL-2R\u03b2\/\u03b3 selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential BASEL, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug (IND) application to conduct a Phase I\/II study evaluating the safety and clinical activity of ANV600 has been accepted by the FDA. The Company will initiate the first two dose escalation cohorts with ANV600...","og_url":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/","og_site_name":"Crypto Insider","article_publisher":"https:\/\/www.facebook.com\/yourcryptoinsider","article_published_time":"2024-05-29T06:00:00+00:00","og_image":[{"url":"https:\/\/ml.globenewswire.com\/media\/MjUzNWRlYjMtMTAxMS00ZjhkLWI1MjgtNDEwODk5ZmY0Nzc5LTEyNDQ0MjE=\/tiny\/Anaveon.png","type":"","width":"","height":""}],"author":"Crypto Insider","twitter_card":"summary_large_image","twitter_misc":{"\u0110\u01b0\u1ee3c vi\u1ebft b\u1edfi":"Crypto Insider","\u01af\u1edbc t\u00ednh th\u1eddi gian \u0111\u1ecdc":"2 ph\u00fat"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/#article","isPartOf":{"@id":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/"},"author":{"name":"Crypto Insider","@id":"https:\/\/cryptoinsider.asia\/#\/schema\/person\/e81ca31713268a414ddbed321d3383d6"},"headline":"Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\/II clinical study","datePublished":"2024-05-29T06:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/"},"wordCount":364,"commentCount":0,"publisher":{"@id":"https:\/\/cryptoinsider.asia\/#organization"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2024\/05\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study.gif","articleSection":["Business","GlobeNewswire"],"inLanguage":"vi","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/","url":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/","name":"Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\/II clinical study - Crypto Insider","isPartOf":{"@id":"https:\/\/cryptoinsider.asia\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/#primaryimage"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2024\/05\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study.gif","datePublished":"2024-05-29T06:00:00+00:00","description":"Crypto and Blockchain News","breadcrumb":{"@id":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/#breadcrumb"},"inLanguage":"vi","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/"]}]},{"@type":"ImageObject","inLanguage":"vi","@id":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/#primaryimage","url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2024\/05\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study.gif","contentUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2024\/05\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study.gif","width":1,"height":1},{"@type":"BreadcrumbList","@id":"https:\/\/cryptoinsider.asia\/vi\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cryptoinsider.asia\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/cryptoinsider.asia\/category\/news\/"},{"@type":"ListItem","position":3,"name":"Business","item":"https:\/\/cryptoinsider.asia\/category\/business\/"},{"@type":"ListItem","position":4,"name":"Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\/II clinical study"}]},{"@type":"WebSite","@id":"https:\/\/cryptoinsider.asia\/vi\/#website","url":"https:\/\/cryptoinsider.asia\/vi\/","name":"Crypto Insider","description":"Crypto and Blockchain News","publisher":{"@id":"https:\/\/cryptoinsider.asia\/vi\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cryptoinsider.asia\/vi\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vi"},{"@type":"Organization","@id":"https:\/\/cryptoinsider.asia\/vi\/#organization","name":"Crypto Insider","url":"https:\/\/cryptoinsider.asia\/vi\/","logo":{"@type":"ImageObject","inLanguage":"vi","@id":"https:\/\/cryptoinsider.asia\/vi\/#\/schema\/logo\/image\/","url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2021\/11\/Logo-crypto-insider.jpeg","contentUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2021\/11\/Logo-crypto-insider.jpeg","width":2048,"height":2048,"caption":"Crypto Insider"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/yourcryptoinsider","https:\/\/www.linkedin.com\/company\/vietnaminsider"]},{"@type":"Person","@id":"https:\/\/cryptoinsider.asia\/#\/schema\/person\/e81ca31713268a414ddbed321d3383d6","name":"Crypto Insider","description":"Tin t\u1ee9c v\u1ec1 Ti\u1ec1n \u0111i\u1ec7n t\u1eed v\u00e0 c\u00f4ng ngh\u1ec7 Blockchain","sameAs":["https:\/\/cryptoinsider.asia"]}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2024\/05\/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study.gif","jetpack-related-posts":[],"jetpack_likes_enabled":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts\/5928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/comments?post=5928"}],"version-history":[{"count":0,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts\/5928\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/media\/5929"}],"wp:attachment":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/media?parent=5928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/categories?post=5928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/tags?post=5928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}